Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336959 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery
A Phase 2 study, sponsored by Mereo BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT01336959 is a Phase 2 study that was terminated before completion, run by Mereo BioPharma. The registered enrollment target is 91 participants.
The verdict
NCT01336959, a Phase 2 study, was terminated before completion, sponsored by Mereo BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass.
Interventions
- DRUG Placebo
- DRUG BCT197 Part A
- DRUG BCT197 Part B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336959
The ClinicalTrials.gov registry entry for NCT01336959 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mereo BioPharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01336959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01336959 about?
NCT01336959 is a clinical study titled "Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery". This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass.
What is the current status of trial NCT01336959?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2011-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01336959?
The interventions under investigation include: Placebo (DRUG), BCT197 Part A (DRUG), BCT197 Part B (DRUG).
Who is sponsoring clinical trial NCT01336959?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.